Introduction: Once severe ischemia has lasted for about 20 minutes, myocardial necrosis ensues, affecting the subendocardium first and then proceeding in a time dependent wave front to reach epicardium about 4 to 6 hours later. Restoration of blood flow before necrosis is transmural, arrests the progression of necrosis and salvages the still viable but ischemic myocardium that would otherwise proceed to necrosis. Aim: The objective is to assess the occurrence of complications of half dose of streptokinase versus full dose of streptokinase in three weeks follow-up following thrombolysis therapy. Material and Methods: Sixty elderly patients with acute myocardial infarction were enrolled in the study, presenting within 12 hours of onset of symptoms and having no contra-indication to thrombolytic therapy at GMC, Jammu for a period of one year w.e.f nov.2017 to oct.2018. Results: Out of the total 60 cases included in our study, 30 (50%) were assigned to the study group and 30 (50%) were included in the control group. Overall, 46 (76.7%) males and 14 (23.3%) females were included in the study. Conclusion: In the present study, we conclude that low dose streptokinase also achieved post-therapy outcome comparable to the standard dose, as assessed clinically and echocardiographically in a shortterm follow-up of three weeks.
Introduction
Acute myocardial infarction (AMI) has been found to be the leading cause of death in elderly over the age of 65 years. It accounts for 80% of deaths in the elderly, with 6.8% of the population of India over 60 years. The mortality in elderly is two-times more after AMI as compared to the younger counterparts 1 . The mortality of infarction increases very steeply with increasing age >65 years with 1-month mortality in the range of 20-30% 2 . Although early studies suggested an increased risk of haemorrrhagic complications in www.jmscr.igmpublication.org Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v7i5.02 the elderly patients receiving thrombolytic therapy 3,4 , large multicentric trials have shown that this fear is unfounded 5,6 . However, two recent studies have shown that streptokinase in conventional doses of 1.5 million units was associated with excess of strokes in patients aged more than 70 years 7 . The risk of cerebral haemorrhage following thrombolysis is small, about 1-2 per 1000 8. Though the traditional dose of streptokinase fixed at 1.5 million units 9 , has been widely accepted, some recent clinical trials have provided non-invasive evidence of reperfusion with half dose streptokinase with comparable results. 10, 11 
Material and Methods
The present work is a hospital based crosssectional study for a period of one year from nov.2017 to oct.2018 that included 60 patients of acute myocardial infarction in elderly that presented within 12 hours of onset of symptoms and had no contraindication to administration of streptokinase for thrombolysis. The patients were randomized into two groups: the study group to whom 7.5 lakh units of streptokinase was administered intravenously over 30 minutes, while the control group received the standard dose of 1.5 million units of streptokinase intravenously over one hour. Detailed history was taken and thorough clinical and biochemical profile was done.AMI was diagnosed by criteria defined by World Health Organization (WHO). Electrocardiogram (ECG) was recorded both at baseline and after 3 hours. Echocardiographic analysis of left ventricular function, left ventricular ejection fraction and left ventricular diastolic dysfunction were calculated at three weeks.
Results
The present study titled "Post-therapy outcome and echocardiographic analysis at three weeks of elderly patients with acute myocardial infarction following thrombolysis therapy" was conducted in Postgraduate Department of Medicine, Government Medical College Hospital, Jammu from November 2017 to October 2018. All the patients included in the study had presented within 12 hours of onset of symptoms and had no contraindication to administration of streptokinase for thrombolysis. The observations made were considered as follows: 
Discussion
Sixty elderly patients with acute myocardial infarction were enrolled in the study, presenting within 12 hours of onset of symptoms and having no contra-indication to thrombolytic therapy. The patients included in the study were randomized into two groups -30 patients in the study (cases) group were thrombolysed with 7.5 lakh units of streptokinase (half dose) over thirty minutes while the rest 30 patients in the control group were administered 1.5 million units of streptokinase (conventional full dose) over one hour. Posttherapy outcome and echocardiographic analysis at three weeks of patients with acute myocardial infarction following thrombolysis therapy were done.
Baseline characteristics:
Both, the study and the control groups were matched for age and gender. Majority of the patients in the study as well as control group had anterior wall myocardial infarction (53.3%) followed by inferior wall myocardial infarction (36.7%). Both the study and control groups were matched for distribution of infarct sites. Most of the patients were in Killip class I and II at presentation in the study (cases) as well as the control group. Twenty-three in the study group and 10 in the control group were in Killip class I, while 7 in the study and 18 in the control group were in Killip class II. None of the patients in the study group were in Killip Class III, while as 2 patients in the control group were in Killip class III. None of the patients were having cardiogenic shock at the time of presentation when administered streptokinase. Severity of cardiac dysfunction was similar in both the study and the control group. Both the groups were matched with respect to Killip class at presentation. The major risk factor in both the groups was smoking, accounting for 60% (18 cases) and 66.67% (20 cases) in the study and the control group, respectively. This was followed by hypertension as a risk factor, comprising 53.33%o (16 cases) and 46.67% (14) in the study and the control groups, respectively. No statistically significant difference was found between study and control groups regarding distribution of risk factors. As per the study protocol, only those patients coming within 12 hours of onset of typical symptoms of acute myocardial infarction were included in the study. The mean therapeutic window (i.e. time from onset of cardiac pain to administration of streptokinase) in the study group was 6.32 ± 2.23 hours while as those in the control group was 4.90 ± 1.95 hours. No statistically significant difference was found in the therapeutic window of both the groups. However, this is a subjective phenomenon and no definite time period has been documented to signify reperfusion. Reperfusion using the criterion of fractional change (Fc) on ECG was achieved in 86.67% (26) and 80% (24) of the patients in the study and the control group, respectively. The difference between the two groups by chi-square test was p = 0.2, which is not statistically significant. According to fractional change, the patients were said to be reperfused if Fc ≥ 0.5 and not reperfused if Fc < 0.5. A fractional change value of Fc ≥ 0.5 had been found to 67% specific and 93% sensitive for predicting a patent artery (Hogg et al. 1988 ) 13 . In a study taking time from streptokinase infusion to peak CPK as a criterion for reperfusion, it was found that peaking of CPK occurred at 9.7 ± 6.3 and 12.3 ± 4.8 hours in those receiving 7.5 lakh units and 1.5 million units of streptokinase, respectively (difference not statistically significant) [Gottlich et al 1988] 14 . In this study, in the group receiving, 7,50,000 IU of streptokinase, 89%) patients showed peaking of CPK-MB within 12 hours, while 67% of patients did so in the group given 1.500,000 IU. This compares well with the data of the present study. The results of our study also corroborate with those of Sivan et al (2003) 11 who analyzed the efficacy and safety of streptokinase in full conventional dose (15 million units), half dose (7.5 lakh) and no thrombolysis in the elderly population (> 75 years). Successful thrombolysis in their study was defined as ST-segment resolution of 50% or more. They concluded that half dose (7.5 lakh units) streptokinase has equal efficacy, better clinical outcome, and reduced rate of complications as compared to full dose of streptokinase.
Post-therapy outcome
Considering the complication rate, the criteria to assess post-therapy outcome/complications clinically included any minor bleed, major bleed, anaphylaxis and haemorrhage. In our study, there was a greater incidence of minor bleed in the control group (patients receiving 1.5 million units of streptokinase) which was statistically significant. However, no major bleed or any other complication was encountered either in the study group (cases) or the control group following thrombolytic therapy. Thus, 7.5 lakh units of streptokinase was safer in elderly patients as compared to 1.5 million units in terms of minor bleeding complications. However, post-myocardial infarction angina occurred in 2 (6.7%) cases among the study group while as no such event occurred in the control group.
Echocardiographic analysis at three weeks:
The results obtained on echocardiographic analysis of patients at 3 weeks after acute myocardial infarction showed that the left ventricular ejection fraction (LVEF) ranged from 44 to 59% in the study group (cases) and 41 to 57%o in the control group. Mean LVEF in the study group (cases) was 50.33 ± 3.92 while in the control group was 49.87 ± 4.94, there was no statistically significant difference of left ventricular ejection fraction at 3 weeks in the two groups as assessed by t-test (p = 0.687). On correlating the echo evaluated LVEF at 3 weeks in patients with reperfusion by fractional change, it was found that the mean LVEF in those reperfused by Fc criterion was 51.82% and 53.10% in the study and control groups, respectively. The t-test for significance gave pvalue of 0.375 (not statistically significant). Thus, thrombolysis with either low (7.5 lakh units) or standard dose (1.5 million units) produces similar variation in left ventricular ejection fraction (LVEF). In a study, the global ejection fraction at 3 months using radionucleotide ventriculography was 50 ± 14 and 45 ± 16 in low and standard dose streptokinase, respectively (Six et al 1990) 15 . Left ventricular diastolic dysfunction (LVDD) assessed by echo at the end of three weeks postmyocardial infarction was present in 22 (73.3%) patients among the study group (cases) and 24 (80.0%) patients among the control group. Twotailed significance (chi-square test) for both the groups came to be 0.761, which was statistically not significant implying that low and standard dose of streptokinase do not alter the postmyocardial infarction outcome in terms of left ventricular diastolic dysfunction. Reperfusion leads to better left ventricular ejection fraction and less ventricular diastolic dysfunction in the post-myocardial infarction period as documented by other studies (White et al.1987) 16 .
Conclusion
In the present study, we conclude that low dose streptokinase also achieved post-therapy outcome comparable to the standard dose, as assessed clinically and echocardiographically in a shortterm follow-up of three weeks. Also, low dose streptokinase (7.5 lakh units) infusion was found to be associated with a lower incidence of
